Clinical and hormonal response to bromocriptin (CB-154) in the galactorrhea syndromes.
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001966:Bromine / Q000627:therapeutic use; D002746:Chlorpromazine / Q000494:pharmacology; D003276:Contraceptives, Oral / Q000009:adverse effects; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000187:drug effects; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood; D011863:Radioimmunoassay; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D003276:Contraceptives, Oral; D004876:Ergot Alkaloids; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D001966:Bromine; D002746:Chlorpromazine